The widespread use of genetic testing in high risk pregnancies has created strong interest in rapid and accurate molecular diagnostics for common chromosomal aneuploidies. We show here that digital polymerase chain reaction (dPCR) can be used for accurate measurement of trisomy 21 (Down's Syndrome), the most common human aneuploidy.
Introduction
At present, amiocentesis and chorionic villus sampling are the most routinely employed clinical procedures to obtain fetal genetic materials for prenatal diagnosis. The gold standard analytical technique to analyze such samples is karyotyping via Giemsa banding; while it is accurate and informative, it is also time consuming and the two weeks between sampling and result can create anxiety for the expectant parents.
Conventional karyotyping is therefore gradually being supplanted by techniques based on polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) 1, 2 .
Although these techniques are substantially faster than karyotyping, they have
limitations. FISH is labor intensive and requires intact cells. Quantitative fluorescence PCR (QF-PCR) techniques depend on the existence of allelic variation in the population
and therefore are not applicable to homozygotic individuals, and furthermore require an electrophoretic separation step after amplification. There have been attempts to use quantitative PCR (Q-PCR) to perform single step amplification and detection, but it is challenging to achieve the required level of quantitation 2 .
Digital PCR is a technique to quantify the amount of DNA in a sample by counting amplifications from single molecules. Digital PCR in principle allows a much higher precision of measurement than Q-PCR, and does not suffer from the limitations of other molecular methods. Briefly, the DNA sample is diluted and aliquoted into compartments or wells such that on average there is less than 1 copy per well. The number of wells that
give a positive signal after a PCR reaction corresponds to the number of DNA template molecules in the original sample. A version of this technique involving the use of 3 magnetic beads in microemulsions has been used for early detection of colorectal tumors 3, 4 and as a sample preparation technique for DNA sequencing 5, 6 . A microfluidic version of digital PCR has been used for single cell gene expression in hematopoietic stem cells 7 and for mapping gene function to organism identity in environmental microbes 8 .
Here we demonstrate the use of microfluidic digital PCR for the detection of 
Sensitivity to Maternal Cell Contamination and Mosaicism
Real world samples are sometimes characterized by fetal mosaicism or contamination with maternal cells. To assess the robustness of the digital PCR method for the detection of fetal aneuploidy in these circumstances, we performed the assay on samples containing mixtures of normal and trisomy 21 genomic DNA in different proportions. The ultimate sensitivity of digital PCR to resolve fetal genotype in the presence of maternal contamination is determined by the number of reactions performed. The larger number of molecules assayed, the better is the confidence with which one can make the determination of normal or aneuploid. This can be calculated precisely, as described below.
If abnormal DNA constitutes ε * 100 % of the total amount of extracted DNA, for every m genomic equivalents of total DNA, there exist 2m copies of a gene on a normal chromosome and m(2+ε) copies of a gene on the abnormal chromosome. The difference of mε is in principle detectable, provided that the difference is at some level greater than the sampling noise, which scales as the square root of copy number. The number of compartments required to achieve k standard deviation of significance can then be estimated (see supporting materials for derivation). k is a function of ε and the number of compartments used. Figure 3 is a plot of k against number of compartments for various percentages of abnormal DNA in a mixture of normal and abnormal DNA, assuming that every three compartments contain one template molecule. In theory, if k is greater than 1.96, one is 95% confident that the sample is not from a normal fetus. Such a confidence interval can be achieved using approximately 4000 compartments for samples containing 7 10% abnormal DNA. In this manner, one can achieve nearly arbitrary sensitivity simply by increasing the scale of the assay.
Our calculations show that a sample containing roughly 10 3 genomic equivalents would enable the determination of normal versus abnormal for sample containing only 10%
abnormal DNA with 95% confidence. Such amount of material can be obtained readily from conventional amniocentesis or chorionic villus sampling.
Conclusion
We described a novel molecular diagnostic technique to measure chromosomal aneuploidy. The method is based on the concept of digital PCR, which involves the precise quantitation of single template molecules. Although this is only a proof-ofprinciple study, we believe that digital PCR would be as competitive as, if not better than, the several molecular diagnostic tools currently practised (such as FISH, QF-PCR and Q-PCR), since it is a rapid, simple, yet precise procedure and is able to detect abnormality with the presence of maternal contamination or fetal chromosomal mosaicism. This method may also be applicable to non-invasive prenatal testing, in which a small amount of fetal DNA is found circulating in the maternal bloodstream.
Supporting Materials
For m genome equivalents, Let Y=copy number of Chromosome 21 and X=copy number of Chromosome 12
The difference between copy numbers of Chr21 and Chr12 = D = Y-X = mε
Require the difference D to be some constant k times the sampling noise √Y
If 1/3 of the panel is used (i.e., 1 positive compartment in every 3 compartments):
N=number of compartments
The response characteristic of digital PCR is developed and presented in Warren et al 7 .
Substitute the expression of Y into the expression of k to obtain the number of compartments N (or PCR reactions required) in order to achieve k standard deviations of significance.
Figure Captions 100% trisomy 60% trisomy 50% trisomy 40% trisomy 30% trisomy 20% trisomy 10% trisomy Figure 3 
